You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
29 Immune modulation and baseline biomarker correlation with clinical benefit following treatment with COM701+nivolumab+/-BMS-986207 in patients with platinum resistant ovarian cancer

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023290012
Dec 20233505
Jan 20245403
Feb 20243002
Mar 20242400
Apr 20244409
May 20242805
Jun 20247405
Jul 20244804
Aug 20241203
Sep 20242602
Oct 20242804
Nov 202422012
Dec 20242605
Jan 20252406
Feb 2025701
Mar 2025002
Apr 2025002
May 2025005
Jun 2025003
Total772090